{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:51:46Z","timestamp":1767966706153,"version":"3.49.0"},"reference-count":110,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1097\/icu.0b013e3283548459","type":"journal-article","created":{"date-parts":[[2012,6,6]],"date-time":"2012-06-06T10:53:57Z","timestamp":1338980037000},"page":"303-316","source":"Crossref","is-referenced-by-count":17,"title":["Anterior segment uses of bevacizumab"],"prefix":"10.1097","volume":"23","author":[{"given":"Irit","family":"Bahar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia N.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruti","family":"Sella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Slomovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-13-20210206","first-page":"1929","article-title":"Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor.","volume":"37","author":"Kvanta","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R2-13-20210206","first-page":"18","article-title":"Requirement for vascular endothelial growth factor in wound-and inflammation-related corneal neovascularization.","volume":"39","author":"Amano","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R3-13-20210206","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/archopht.1996.01100130062010","article-title":"Inhibition of VEGF prevents retinal ischemia-associated iris neovascularization in a primate.","volume":"114","author":"Adamis","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"R4-13-20210206","first-page":"1029","article-title":"Vascular permeability actorvascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.","volume":"146","author":"Dvorak","year":"1995","journal-title":"Am J Pathol"},{"key":"R5-13-20210206","first-page":"3974","article-title":"Mechanisms of retinal and choroidal neovascularization.","volume":"35","author":"DAmore","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R8-13-20210206","first-page":"961","article-title":"Vascular endothelial growth factor (rh VEGF165) stimulates direct angiogenesis in the rabbit cornea.","volume":"8","author":"Phillips","year":"1994","journal-title":"In Vivo"},{"key":"R9-13-20210206","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.","volume":"331","author":"Aiello","year":"1994","journal-title":"N Engl J Med"},{"key":"R10-13-20210206","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF00192885","article-title":"Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects.","volume":"73","author":"Battegay","year":"1995","journal-title":"J Mol Med"},{"key":"R11-13-20210206","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1242\/dev.114.2.521","article-title":"Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation.","volume":"114","author":"Breier","year":"1992","journal-title":"Development"},{"key":"R12-13-20210206","first-page":"574","article-title":"Vascular endothelial growth factorvascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model.","volume":"145","author":"Miller","year":"1994","journal-title":"Am J Pathol"},{"key":"R13-13-20210206","first-page":"645","article-title":"Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases.","volume":"72","author":"Peer","year":"1995","journal-title":"Lab Invest"},{"key":"R14-13-20210206","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/archopht.1996.01100140172010","article-title":"Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate.","volume":"114","author":"Tolentino","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"R15-13-20210206","first-page":"2514","article-title":"Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas.","volume":"41","author":"Philipp","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R16-13-20210206","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/00003226-200110000-00013","article-title":"Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia.","volume":"20","author":"Lee","year":"2001","journal-title":"Cornea"},{"key":"R17-13-20210206","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"R18-13-20210206","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1001\/archopht.1983.01040010640024","article-title":"Effects of prednisolone and medroxyprogesterone on corneal wound healing, ulceration, and neovascularization.","volume":"101","author":"Phillips","year":"1983","journal-title":"Arch Ophthalmol"},{"key":"R19-13-20210206","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00417-005-0036-1","article-title":"Inhibitory effect of triamcinolone acetonide on corneal neovascularization.","volume":"244","author":"Murata","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R20-13-20210206","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/01.ico.0000220768.11778.60","article-title":"Prevention of corneal neovascularization: evaluation of various commercially available compounds in an experimental rat model.","volume":"25","author":"Riazi-Esfahani","year":"2006","journal-title":"Cornea"},{"key":"R21-13-20210206","first-page":"274","article-title":"Corneal neovascularization induced by xenografts or chemical cautery: inhibition by cyclosporin A.","volume":"38","author":"Benelli","year":"1997","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R22-13-20210206","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s004170050387","article-title":"Topical application of methotrexate for inhibition of corneal angiogenesis.","volume":"237","author":"Joussen","year":"1999","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R23-13-20210206","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/archopht.120.8.1063","article-title":"Angiostatin inhibits and regresses corneal neovascularization.","volume":"120","author":"Ambati","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"R24-13-20210206","doi-asserted-by":"crossref","first-page":"9828","DOI":"10.1128\/JVI.75.20.9828-9835.2001","article-title":"Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis.","volume":"75","author":"Zheng","year":"2001","journal-title":"J Virol"},{"key":"R25-13-20210206","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ajo.2010.04.024","article-title":"Inhibition of corneal neovascularization by topical bevacizumab (anti-VEGF) and Sunitinib (anti-VEGF and Anti-PDGF) in an animal model.","volume":"150","author":"Perez-Santonja","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"R26-13-20210206","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1755-3768.2009.01571.x","article-title":"The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization.","volume":"88","author":"Habot-Wilner","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"R27-13-20210206","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3109\/02713683.2011.601840","article-title":"The impact of subconjunctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model.","volume":"36","author":"Sener","year":"2011","journal-title":"Curr Eye Res"},{"key":"R28-13-20210206","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1590\/S1807-59322011000800023","article-title":"The effect of subconjunctival bevacizumab on corneal neovascularization, inflammation and re-epithelization in a rabbit model.","volume":"66","author":"Mello","year":"2011","journal-title":"Clinics (Sao Paulo)"},{"key":"R29-13-20210206","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/ICO.0b013e31818b8be0","article-title":"Evaluation of cytotoxic effects of bevacizumab on human corneal cells.","volume":"28","author":"Chalam","year":"2009","journal-title":"Cornea"},{"key":"R30-13-20210206","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1167\/iovs.07-1129","article-title":"Safety profile of topical VEGF neutralization at the cornea.","volume":"50","author":"Bock","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R31-13-20210206","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1167\/iovs.08-2805","article-title":"Bevacizumab application delays epithelial healing in rabbit cornea.","volume":"50","author":"Kim","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R32-13-20210206","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1600-0420.2007.01049.x","article-title":"Bevacizumab Study Group. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.","volume":"86","author":"Yoeruek","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"R33-13-20210206","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","article-title":"Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study.","volume":"127","author":"Dastjerdi","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"R34-13-20210206","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ophtha.2008.02.013","article-title":"The effect of topical bevacizumab on corneal neovascularization.","volume":"115","author":"Kim","year":"2008","journal-title":"Ophthalmology"},{"key":"R35-13-20210206","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/ICO.0b013e3181e458c5","article-title":"Subconjunctival injection of bevacizumab in the treatment of corneal neovascularization associated with lipid deposition.","volume":"30","author":"Chu","year":"2011","journal-title":"Cornea"},{"key":"R36-13-20210206","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/ICO.0b013e31820cd3f4","article-title":"Compensatory growth factor and cytokine response in tears after subconjunctival bevacizumab injection.","volume":"30","author":"Jeong","year":"2011","journal-title":"Cornea"},{"key":"R37-13-20210206","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1097\/ICO.0b013e3181d92834","article-title":"Perilimbal bevacizumab injection for interface neovascularization after deep anterior lamellar keratoplasty.","volume":"29","author":"Foroutan","year":"2010","journal-title":"Cornea"},{"key":"R39-13-20210206","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","article-title":"Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization.","volume":"247","author":"Koenig","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R40-13-20210206","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ICO.0b013e31817786ad","article-title":"Subconjunctival bevacizumab for corneal neovascularization.","volume":"27","author":"Doctor","year":"2008","journal-title":"Cornea"},{"key":"R41-13-20210206","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/ICO.0b013e318159019f","article-title":"Subconjunctival bevacizumab injection for corneal neovascularization.","volume":"27","author":"Bahar","year":"2008","journal-title":"Cornea"},{"key":"R42-13-20210206","doi-asserted-by":"crossref","first-page":"8718","DOI":"10.1167\/iovs.11-7871","article-title":"Corneal penetration of topical and subconjunctival bevacizumab.","volume":"52","author":"Dastjerdi","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R43-13-20210206","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000322061","article-title":"Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats.","volume":"46","author":"Hashemian","year":"2011","journal-title":"Ophthalmic Res"},{"key":"R44-13-20210206","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00417-009-1170-y","article-title":"Avastin use in high risk corneal transplantation.","volume":"247","author":"Vassileva","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R45-13-20210206","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/ICO.0b013e31819839f9","article-title":"Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy.","volume":"28","author":"Oh","year":"2009","journal-title":"Cornea"},{"key":"R46-13-20210206","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/ICO.0b013e31821379aa","article-title":"Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization.","volume":"30","author":"Yeung","year":"2011","journal-title":"Cornea"},{"key":"R47-13-20210206","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3109\/15569527.2011.573834","article-title":"Subconjunctival bevacizumab for corneal neovascularization secondary to topical anesthetic abuse.","volume":"30","author":"Georgakopoulos","year":"2011","journal-title":"Cutan Ocul Toxicol"},{"key":"R48-13-20210206","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/ICO.0b013e3181e291a6","article-title":"Deep intrastromal bevacizumab injection for management of corneal stromal vascularization after deep anterior lamellar keratoplasty, a novel technique.","volume":"30","author":"Hashemian","year":"2011","journal-title":"Cornea"},{"key":"R49-13-20210206","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3109\/02713680903429007","article-title":"Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.","volume":"35","author":"Avisar","year":"2010","journal-title":"Curr Eye Res"},{"key":"R50-13-20210206","first-page":"2326","article-title":"Effect of subconjunctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization.","volume":"15","author":"Dratviman-Storobinsky","year":"2009","journal-title":"Mol Vis"},{"key":"R51-13-20210206","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/ICO.0b013e3181861cc9","article-title":"Bevacizumab (avastin) for corneal neovascularization: corneal light shield soaked application.","volume":"28","author":"Mackenzie","year":"2009","journal-title":"Cornea"},{"key":"R52-13-20210206","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1442-9071.2010.02252.x","article-title":"Inhibition of corneal neovascularization after alkali burn: comparison of different doses of bevacizumab in monotherapy or associated with dexamethasone.","volume":"38","author":"Hoffart","year":"2010","journal-title":"Clin Experiment Ophthalmol"},{"key":"R53-13-20210206","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/ICO.0b013e3181b1c82f","article-title":"The effect of subconjunctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits.","volume":"29","author":"Kang","year":"2010","journal-title":"Cornea"},{"key":"R54-13-20210206","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/ICO.0b013e3181dc81a0","article-title":"Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab for corneal neovascularization.","volume":"30","author":"You","year":"2011","journal-title":"Cornea"},{"key":"R55-13-20210206","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/ICO.0b013e318180e50f","article-title":"Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery.","volume":"27","author":"Gerten","year":"2008","journal-title":"Cornea"},{"key":"R56-13-20210206","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1097\/ICO.0b013e31817c41e3","article-title":"Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization.","volume":"27","author":"Qian","year":"2008","journal-title":"Cornea"},{"key":"R57-13-20210206","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0065-1281(96)80038-9","article-title":"Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-beta and tumor necrosis factor-alpha in the pterygium.","volume":"98","author":"Kria","year":"1996","journal-title":"Acta Histochem"},{"key":"R58-13-20210206","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s004170050144","article-title":"Growth factors in cultured pterygium fibroblasts: immunohistochemical and ELISA analysis.","volume":"236","author":"Kria","year":"1998","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R59-13-20210206","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/00003226-199709000-00010","article-title":"Immunolocalization of bFGF in pterygia: association with mast cells.","volume":"16","author":"Powers","year":"1997","journal-title":"Cornea"},{"key":"R60-13-20210206","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/sj.eye.6702433","article-title":"Endothelial progenitor cells in pterygium pathogenesis.","volume":"21","author":"Lee","year":"2007","journal-title":"Eye"},{"key":"R61-13-20210206","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00003226-200307000-00015","article-title":"Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia.","volume":"22","author":"Jin","year":"2003","journal-title":"Cornea"},{"key":"R62-13-20210206","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/ICO.0b013e31821c9b44","article-title":"A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: preliminary results.","volume":"30","author":"Enkvetchakul","year":"2011","journal-title":"Cornea"},{"key":"R63-13-20210206","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/jop.2010.0094","article-title":"Bevacizumab and ocular wound healing after primary pterygium excision.","volume":"27","author":"Banifatemi","year":"2011","journal-title":"J Ocul Pharmacol Ther"},{"key":"R64-13-20210206","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/ICO.0b013e31820ca63f","article-title":"Subconjunctival bevacizumab immediately after excision of primary pterygium: the first clinical trial.","volume":"30","author":"Shenasi","year":"2011","journal-title":"Cornea"},{"key":"R65-13-20210206","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/02713680903395273","article-title":"Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium.","volume":"35","author":"Fallah","year":"2010","journal-title":"Curr Eye Res"},{"key":"R66-13-20210206","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/ICO.0b013e3181e16d67","article-title":"Efficacy of intralesional bevacizumab injection in decreasing pterygium size.","volume":"30","author":"Fallah Tafti","year":"2011","journal-title":"Cornea"},{"key":"R67-13-20210206","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/02713680701799101","article-title":"Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.","volume":"33","author":"Bahar","year":"2008","journal-title":"Curr Eye Res"},{"key":"R68-13-20210206","first-page":"179","article-title":"Subconjunctival bevacizumab injection in treatment of pterygium.","volume":"49","author":"Besharati","year":"2011","journal-title":"Acta Med Iran"},{"key":"R69-13-20210206","first-page":"28","article-title":"Multiple subconjunctival bevacizumab for advanced primary pterygium.","volume":"42","author":"Saxena","year":"2010","journal-title":"Ann Ophthalmol (Skokie)"},{"key":"R71-13-20210206","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/ICO.0b013e3181822615","article-title":"Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium.","volume":"28","author":"Wu","year":"2009","journal-title":"Cornea"},{"key":"R72-13-20210206","first-page":"1557","article-title":"Treatment of neovascular glaucoma.","volume":"11","author":"Wand","year":"1979","journal-title":"Ann Ophthalmol"},{"key":"R75-13-20210206","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/08820530902800801","article-title":"Neovascular glaucoma: etiology, diagnosis and prognosis.","volume":"24","author":"Shazly","year":"2009","journal-title":"Semin Ophthalmol"},{"key":"R76-13-20210206","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.ophtha.2004.11.045","article-title":"Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema.","volume":"112","author":"Funatsu","year":"2005","journal-title":"Ophthalmology"},{"key":"R77-13-20210206","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/bjo.2008.151472","article-title":"Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab.","volume":"93","author":"Moraczewski","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R78-13-20210206","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0161-6420(89)32946-0","article-title":"The efficacy of panretinal photocoagulation for neovascularization of the iris after central retinal artery obstruction.","volume":"96","author":"Duker","year":"1989","journal-title":"Ophthalmology"},{"key":"R79-13-20210206","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ajo.2006.02.045","article-title":"Intracameral bevacizumab for iris rubeosis.","volume":"142","author":"Grisanti","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R80-13-20210206","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/archophthalmol.2010.350","article-title":"Intravitreal bevacizumab in refractory neovascular glaucoma: a prospective, observational case series.","volume":"129","author":"Kotecha","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"R82-13-20210206","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/112067210801800214","article-title":"Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma.","volume":"18","author":"Chalam","year":"2008","journal-title":"Eur J Ophthalmol"},{"key":"R84-13-20210206","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1755-3768.2008.01353.x","article-title":"Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy.","volume":"87","author":"Jiang","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"R85-13-20210206","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1755-3768.2008.01355.x","article-title":"Bevacizumab as adjuvant for neovascular glaucoma.","volume":"88","author":"Beutel","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"R86-13-20210206","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000327364","article-title":"Intracameral injection of bevacizumab for the treatment of neovascular glaucoma.","volume":"226","author":"Wolf","year":"2011","journal-title":"Ophthalmologica"},{"key":"R87-13-20210206","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1089\/jop.2011.0059","article-title":"Clinical outcome and changes in aqueous vascular endothelial growth factor levels after intravitreal bevacizumab for iris neovascularization and neovascular glaucoma: a retrospective two-dose comparative study.","volume":"28","author":"Sasamoto","year":"2012","journal-title":"J Ocul Pharmacol Ther"},{"key":"R88-13-20210206","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.ajo.2006.06.066","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.","volume":"142","author":"Iliev","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R89-13-20210206","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3928\/1542-8877-20060301-11","article-title":"Intravitreal bevacizumab in a patient with neovascular glaucoma.","volume":"37","author":"Kahook","year":"2006","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"R90-13-20210206","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/01.iae.0000230425.31296.3b","article-title":"3rd, Albert MA Jr, Mays A, et al. Regression of neovascular iris vessels by intravitreal injection of bevacizumab.","volume":"26","author":"Mason","year":"2006","journal-title":"Retina"},{"key":"R91-13-20210206","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1089\/jop.2007.0036","article-title":"Role of intravitreal bevacizumab in neovascular glaucoma.","volume":"23","author":"Gheith","year":"2007","journal-title":"J Ocul Pharmacol Ther"},{"key":"R92-13-20210206","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1442-9071.2007.01521.x","article-title":"Bevacizumab (Avastin) for the treatment of neovascular glaucoma.","volume":"35","author":"Chilov","year":"2007","journal-title":"Clin Experiment Ophthalmol"},{"key":"R93-13-20210206","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/IJG.0b013e3180457c47","article-title":"Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma.","volume":"16","author":"Yazdani","year":"2007","journal-title":"J Glaucoma"},{"key":"R94-13-20210206","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/00006982-200603000-00017","article-title":"Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection.","volume":"26","author":"Davidorf","year":"2006","journal-title":"Retina"},{"key":"R95-13-20210206","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ajo.2006.02.015","article-title":"Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy.","volume":"142","author":"Oshima","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R96-13-20210206","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/bjo.2008.145714","article-title":"Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma.","volume":"93","author":"Grover","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R97-13-20210206","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00006982-200603000-00016","article-title":"Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.","volume":"26","author":"Avery","year":"2006","journal-title":"Retina"},{"key":"R99-13-20210206","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/IJG.0b013e318170a747","article-title":"Intracameral bevacizumab (Avastin) for neovascular glaucoma: a pilot study in 6 patients.","volume":"18","author":"Duch","year":"2009","journal-title":"J Glaucoma"},{"key":"R100-13-20210206","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/IAE.0b013e3181679c0b","article-title":"Combination intravitreal bevacizumabpanretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma.","volume":"28","author":"Ehlers","year":"2008","journal-title":"Retina"},{"key":"R101-13-20210206","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0161-6420(93)31557-5","article-title":"Molteno tube implantation for neovascular glaucoma. Long-term results and factors influencing the outcome.","volume":"100","author":"Mermoud","year":"1993","journal-title":"Ophthalmology"},{"key":"R102-13-20210206","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/S0161-6420(01)00889-2","article-title":"Cyclophotocoagulation: a report by the American Academy of Ophthalmology.","volume":"108","author":"Pastor","year":"2001","journal-title":"Ophthalmology"},{"key":"R103-13-20210206","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3129\/i09-108","article-title":"Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy.","volume":"44","author":"Eid","year":"2009","journal-title":"Can J Ophthalmol"},{"key":"R105-13-20210206","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/jop.2009.0055","article-title":"Adjunctive intravitreal bevacizumab-combined trabeculectomy versus trabeculectomy alone in the treatment of neovascular glaucoma.","volume":"26","author":"Chen","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"key":"R106-13-20210206","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1755-3768.2009.01648.x","article-title":"Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma.","volume":"88","author":"Saito","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"R107-13-20210206","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/IJG.0b013e3181d9ce12","article-title":"Combined intravitreal bevacizumab and trabeculectomy with mitomycin C versus trabeculectomy with mitomycin C alone for neovascular glaucoma.","volume":"20","author":"Takihara","year":"2011","journal-title":"J Glaucoma"},{"key":"R108-13-20210206","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/IJG.0b013e3181ccb794","article-title":"Management of neovascular glaucoma with panretinal photocoagulation, intravitreal bevacizumab, and subsequent trabeculectomy with mitomycin C.","volume":"19","author":"Alkawas","year":"2010","journal-title":"J Glaucoma"},{"key":"R109-13-20210206","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/01.ijg.0000212270.27359.64","article-title":"Trabeculectomy with mitomycin C combined with direct cauterization of peripheral iris in the management of neovascular glaucoma.","volume":"15","author":"Elgin","year":"2006","journal-title":"J Glaucoma"},{"key":"R110-13-20210206","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1136\/bjo.2007.129833","article-title":"Efficacy of intravitreal bevacizumab as adjunctive treatment with pars plana vitrectomy, endolaser photocoagulation, and trabeculectomy for neovascular glaucoma.","volume":"92","author":"Miki","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R111-13-20210206","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/eye.2008.113","article-title":"Intravitreal bevacizumab and augmented trabeculectomy for neovascular glaucoma in young diabetic patients.","volume":"23","author":"Cornish","year":"2009","journal-title":"Eye (Lond)"},{"key":"R112-13-20210206","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000099248","article-title":"Intravitreal bevacizumab for filtering surgery.","volume":"39","author":"Jonas","year":"2007","journal-title":"Ophthalmic Res"},{"key":"R113-13-20210206","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/IJG.0b013e31815f5345","article-title":"Vascular changes after intra-bleb injection of bevacizumab.","volume":"17","author":"Coote","year":"2008","journal-title":"J Glaucoma"},{"key":"R114-13-20210206","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00417-010-1406-x","article-title":"Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients.","volume":"248","author":"Sugimoto","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R115-13-20210206","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/112067210901900414","article-title":"Intravitreal bevacizumab as an adjunct treatment for neovascular glaucoma.","volume":"19","author":"Hasanreisoglu","year":"2009","journal-title":"Eur J Ophthalmol"},{"key":"R116-13-20210206","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1177\/112067210901900318","article-title":"The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma.","volume":"19","author":"Gupta","year":"2009","journal-title":"Eur J Ophthalmol"},{"key":"R117-13-20210206","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/IJG.0b013e3181997211","article-title":"Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial.","volume":"18","author":"Yazdani","year":"2009","journal-title":"J Glaucoma"},{"key":"R118-13-20210206","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/ICO.0b013e3180de1d0a","article-title":"Safety profile of bevacizumab on cultured human corneal cells.","volume":"26","author":"Yoeruek","year":"2007","journal-title":"Cornea"},{"key":"R119-13-20210206","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ajo.2008.05.036","article-title":"Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans.","volume":"146","author":"Krohne","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R120-13-20210206","first-page":"841","article-title":"Intravitreal bevacizumab with or without mitomycin C trabeculectomy in the treatment of neovascular glaucoma.","volume":"5","author":"Marey","year":"2011","journal-title":"Clin Ophthalmol"}],"container-title":["Current Opinion in Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICU.0b013e3283548459","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T18:59:35Z","timestamp":1642359575000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00055735-201207000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":110,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/icu.0b013e3283548459","relation":{},"ISSN":["1040-8738"],"issn-type":[{"value":"1040-8738","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}